1-13 of 13
Michael G. Rosenblum
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC

Hong Zhou, Khalid A. Mohamedali, Ana Maria Gonzalez-Angulo, Yu Cao, Mary Migliorini, Lawrence H. Cheung, Janine LoBello, Xiudong Lei, Yuan Qi, Walter N. Hittelman, Jeffrey A. Winkles, Nhan L. Tran, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (11): 2688–2705.
https://doi.org/10.1158/1535-7163.MCT-14-0346
Published: 03 November 2014
View articletitled, Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC
Open the PDF for Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC in another window
Includes: Supplementary data
Journal Articles

Abstract C231: Novel, fully-human GrB-containing constructs targeting the Fn14 receptor for TWEAK on solid tumor cells.

Hong Zhou, Mary Migliorini, Walter Hittelman, Suhendan Ekmekcioglu, Nhan Tran, Janine LoBello, Jeffrey A. Winkles, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C231.
https://doi.org/10.1158/1535-7163.TARG-13-C231
Published: 01 November 2013
View articletitled, Abstract C231: Novel, fully-human GrB-containing constructs targeting the Fn14 receptor for TWEAK on solid tumor cells.
Journal Articles

The Functionalized Human Serine Protease Granzyme B/VEGF121 Targets Tumor Vasculature and Ablates Tumor Growth

Khalid A. Mohamedali, Yu Cao, Lawrence H. Cheung, Walter N. Hittelman, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (10): 2055–2066.
https://doi.org/10.1158/1535-7163.MCT-13-0165
Published: 07 October 2013
View articletitled, The Functionalized Human Serine Protease Granzyme B/VEGF121 Targets Tumor Vasculature and Ablates Tumor Growth
Open the PDF for The Functionalized Human Serine Protease Granzyme B/VEGF121 Targets Tumor Vasculature and Ablates Tumor Growth in another window
Includes: Supplementary data
Journal Articles

Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu

Yu Cao, Khalid A. Mohamedali, John W. Marks, Lawrence H. Cheung, Walter N. Hittelman, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 979–991.
https://doi.org/10.1158/1535-7163.MCT-13-0002
Published: 09 June 2013
View articletitled, Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu
Open the PDF for Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu in another window
Journal Articles

Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity

Yu Cao, James D. Marks, Qian Huang, Stephen I. Rudnick, Chiyi Xiong, Walter N. Hittelman, Xiaoxia Wen, John W. Marks, Lawrence H. Cheung, Kim Boland, Chun Li, Gregory P. Adams, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (1): 143–153.
https://doi.org/10.1158/1535-7163.MCT-11-0519
Published: 09 January 2012
View articletitled, Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity
Open the PDF for Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity in another window
Includes: Supplementary data
Journal Articles

Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells

Hong Zhou, John W. Marks, Walter N. Hittelman, Hideo Yagita, Lawrence H. Cheung, Michael G. Rosenblum, Jeffrey A. Winkles
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (7): 1276–1288.
https://doi.org/10.1158/1535-7163.MCT-11-0161
Published: 06 July 2011
View articletitled, Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells
Open the PDF for Development and Characterization of a Potent Immunoconjugate Targeting the Fn14 Receptor on Solid Tumor Cells in another window
Journal Articles

Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors

Xiaoqin Yuan, Xinjian Lin, Gerald Manorek, Isao Kanatani, Lawrence H. Cheung, Michael G. Rosenblum, Stephen B. Howell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (7): 1906–1915.
https://doi.org/10.1158/1535-7163.MCT-09-0106
Published: 14 July 2009
View articletitled, Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors
Open the PDF for Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors in another window
Journal Articles

Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis

Jorge L. Martínez-Torrecuadrada, Lawrence H. Cheung, Paula López-Serra, Rodrigo Barderas, Marta Cañamero, Sergio Ferreiro, Michael G. Rosenblum, J. Ignacio Casal
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (4): 862–873.
https://doi.org/10.1158/1535-7163.MCT-07-0394
Published: 15 April 2008
View articletitled, Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis
Open the PDF for Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis in another window
Journal Articles

The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA

Mi-Ae Lyu, Lawrence H. Cheung, Walter N. Hittelman, John W. Marks, Ricardo C.T. Aguiar, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (2): 460–470.
https://doi.org/10.1158/1535-7163.MCT-06-0254
Published: 16 February 2007
View articletitled, The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA
Open the PDF for The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA in another window
Journal Articles

The immunocytokine scFv23/TNF sensitizes HER-2/neu–overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1

Mi-Ae Lyu, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (8): 1205–1213.
https://doi.org/10.1158/1535-7163.MCT-05-0014
Published: 10 August 2005
View articletitled, The immunocytokine scFv23/TNF sensitizes HER-2/neu–overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1
Open the PDF for The immunocytokine scFv23/TNF sensitizes HER-2/neu–overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1 in another window
Journal Articles

Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells

Kapil Mehta, Larry Ocanas, Fabio Malavasi, John W. Marks, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (3): 345–352.
https://doi.org/10.1158/1535-7163.345.3.3
Published: 16 March 2004
View articletitled, Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells
Open the PDF for Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells in another window
Journal Articles

Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents

Yuying Liu, Lawrence H. Cheung, Walter N. Hittelman, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2003) 2 (12): 1341–1350.
Published: 05 January 2004
View articletitled, Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents
Open the PDF for Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents in another window
Journal Articles

Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: Directed apoptotic events in vascular endothelial cells

Yuying Liu, Lawrence H. Cheung, Philip Thorpe, Michael G. Rosenblum
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2003) 2 (10): 949–959.
Published: 24 October 2003
View articletitled, Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: Directed apoptotic events in vascular endothelial cells
Open the PDF for Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: Directed apoptotic events in vascular endothelial cells in another window